

Evaluation of IL-17D in Host Immunity to Group A *Streptococcus* Infection

Allen Washington, Jr.,* Nissi Varki,*[†] J. Andrés Valderrama,[‡] Victor Nizet,^{‡,§} and Jack D. Bui*

IL-17D is a cytokine that belongs to the IL-17 family and is conserved in vertebrates and invertebrates. In contrast to IL-17A and IL-17E, which are expressed in Th17 cells, IL-17D is expressed broadly in nonimmune cells. IL-17D can promote immune responses to cancer and viruses in part by inducing chemokines and recruiting innate immune cells such as NK cells. Although bacterial infection can induce IL-17D in fish and invertebrates, the role of mammalian IL-17D in antibacterial immunity has not been established. To determine whether IL-17D has a role in mediating host defense against bacterial infections, we studied i.p. infection by group A *Streptococcus* (GAS) in wild-type (WT) and *Il17d*^{-/-} mice. Compared with WT animals, mice deficient in IL-17D experienced decreased survival, had greater weight loss, and showed increased bacterial burden in the kidney and peritoneal cavity following GAS challenge. In WT animals, IL-17D transcript was induced by GAS infection and correlated to increased levels of chemokine CCL2 and greater neutrophil recruitment. Of note, GAS-mediated IL-17D induction in nonimmune cells required live bacteria, suggesting that processes beyond recognition of pathogen-associated molecular patterns were required for IL-17D induction. Based on our results, we propose a model in which nonimmune cells can discriminate between nonviable and viable GAS cells, responding only to the latter by inducing IL-17D. *The Journal of Immunology*, 2020, 205: 000–000.

Interleukin-17 cytokines include six members (A–F) that exhibit functional roles in inflammation, autoimmunity, and cancer (1, 2). In contrast to IL-17A and IL-17E that are mostly expressed in T cells, IL-17D is expressed broadly outside of the hematopoietic compartment and has limited expression in bone marrow, thymus, and spleen (3). IL-17B and IL-17C are also expressed in nonimmune cells and induce similar sets of downstream genes as IL-17A (3–6). IL-17A and IL-17C protect the host from various bacterial species in experimental infection models (7–11). IL-17E (also known as IL-25), which is unlike other cytokines in the family, promotes Th2 immune responses and mediates immunity against parasites (12). IL-17B, the least understood IL-17 member with respect to pathogen responses, antagonizes IL-17E signaling and thus may counteract excessive inflammatory processes (13).

We previously found IL-17D to have roles in antitumor and antiviral immunity via induction of the chemokine CCL2 and recruitment of NK cells (14–18). Additionally, we and others have shown that IL-17D induces some overlapping sets of genes downstream of IL-17A, including IL-8 and CCL2 (3, 14). In experimental tumor models, exogenous or tumor-expressed IL-17D was sufficient to cause growth delay or tumor rejection (14, 15). IL-17D is regulated by the oxidative stress sensor NF erythroid-derived 2–like 2 (Nrf2) (16), and we have previously described that oxidative stressors and viral infection activate Nrf2, triggering IL-17D expression and immune cell recruitment (16–18). *Il17d*^{-/-} mice are consequently more susceptible to murine CMV infection and carcinogen-induced tumors (16, 17).

The role of IL-17D in antibacterial immunity is relatively unexplored in mammals, but studies of IL-17D homologs in fish and invertebrate animal models have suggested a protective role (19–23). In fish, *Il17d* is expressed constitutively and further increased in response to Gram-negative bacterial challenge in organs such as the skin and head kidney (19, 20); similar responses have been demonstrated in marine invertebrates, such as oysters and amphioxus (22, 23). In addition, both Gram-negative live bacteria and LPS induce *Il17d* in skin cells of lampreys in vitro (21).

In mammals, IL-17 cytokines such as IL-17A and IL-17E are induced in CD4⁺ T cells by retinoic acid–related orphan nuclear receptor, ROR γ t and ROR α (24–26); epithelial cell IL-17C is induced in response to Gram-negative bacteria (4, 27). Similarly, IL-17E in epithelial cells is induced upon detecting extracellular helminths through succinate (28, 29). In mice, we found IL-17D to be induced by viral infection, constitutively expressed in immunogenic cancer cells, and directly induced by the antioxidant transcription factor Nrf2 (14, 16, 17). It is not clear whether bacterial infection or components induce IL-17D in mammalian systems.

Streptococcus pyogenes, also known as group A *Streptococcus* (GAS), is a leading Gram-positive human bacterial pathogen associated with a wide range of pathological outcomes, from simple pharyngitis and skin infection, to invasive necrotizing fasciitis and

*Department of Pathology, University of California, San Diego, La Jolla, CA 92093; [†]Glycobiology Research and Training Center, University of California, San Diego, La Jolla, CA 92093; [‡]Department of Pediatrics, University of California, San Diego, La Jolla, CA 92161; and [§]Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093

ORCID: 0000-0001-9839-1254 (N.V.); 0000-0003-3847-0422 (V.N.); 0000-0002-9324-368X (J.D.B.).

Received for publication December 16, 2019. Accepted for publication September 22, 2020.

This work was supported by the Hartwell Foundation (to J.D.B.) and by National Institutes of Health/National Institute of Allergy and Infectious Diseases Grant 1R21AI149023 (to J.D.B.).

Address correspondence and reprint requests to Dr. Jack D. Bui, Department of Pathology, University of California, San Diego, 9500 Gilman Drive MC 0612, La Jolla, CA 92093-0612. E-mail address: jrbui@ucsd.edu

The online version of this article contains supplemental material.

Abbreviations used in this article: Ct, cycle threshold; GAS, group A *Streptococcus*; MOI, multiplicity of infection; NAC, *N*-acetyl-L-cysteine; Nrf2, NF erythroid-derived 2–like 2; PAMP, pathogen-associated molecular pattern; PDTC, ammonium pyrrolidine dithiocarbamate; PEC, peritoneal exudate cell; PRR, pattern recognition receptor; ROS, reactive oxygen species; THA, Todd–Hewitt broth agar; WT, wild-type.

Copyright © 2020 by The American Association of Immunologists, Inc. 0022-1767/20/\$37.50

toxic shock syndrome, and importantly, to postinfectious sequelae, including rheumatic heart disease and glomerulonephritis (30–32). GAS expresses pore-forming toxins (including streptolysins S and O) and extracellular proteases that can induce cellular damage and organ system dysfunction during invasive infection (30, 33). A robust inflammatory response to GAS infection is catalyzed by release of cytokines by immune cells that sense bacterial components or cellular damage molecules (34, 35). GAS infection also stimulates generation of reactive oxygen species (ROS) (36, 37), a cellular mechanism of inhibition for bacterial replication that simultaneously promotes inflammatory cell death (34, 38, 39). Because ROS are known inducer molecules of IL-17D, we hypothesized that IL-17D would be induced and potentially play a protective role during GAS infection.

Materials and Methods

Mice

The University of California, San Diego, Institutional Animal Care and Use Committee approved all animal use and procedures (protocol no. S06201). C57BL/6 and IL-17D-deficient (16, 17) mice were housed in specific pathogen-free conditions prior to use. Mice were between 6 and 12 wk old and were age and sex matched across experiments.

In vivo GAS murine infection model

Wild-type (WT) GAS strain 5448 was isolated from a patient with necrotizing fasciitis and toxic shock syndrome (40) and is representative of the globally disseminated serotype M1T1 clone that is the predominant cause of life-threatening invasive GAS infections (41). Mice were injected i.p. with the indicated inoculum of GAS in a total volume of 200 μ l PBS. Each inoculum was prepared by growing GAS overnight in Todd–Hewitt broth (Teknova) and adjusting the concentration according to the spectrophotometric OD 600 reading (35). Inoculum CFU were confirmed by serial dilution plating on Todd–Hewitt broth agar (THA). One-time injection of 200 mg/kg *N*-acetyl-L-cysteine (NAC) in PBS was conducted 4 h prior to GAS infection. Anti-CCL2 polyclonal Ab or control IgG (R&D Systems) was coinjected with GAS. For survival assessment, mice were monitored at least every 12 h to record the body weight and survey health status including signs of lethargy.

Peritoneal exudate and cells were collected by lavage with 2.5 ml PBS. Biopsies of kidney, spleen, lung, and the heart of each mouse were collected to determine GAS burden. The tissues were weighed and homogenized in 1 ml PBS or RPMI medium containing 2% FBS through a 70- μ m strainer. Homogenized tissues were serially diluted 10-fold, and 50 or 10 μ l from each aliquot were cultured overnight on THA at 36.5°C. The measurement of CFU per gram was determined based on total CFU in 1 ml divided by the weight of organ; samples without a colony were arbitrarily assigned as 1 CFU/ml and divided by the weight of the organ to provide graphable nonzero data points.

In vitro GAS infection of cultured cells

Heat-killed GAS were prepared by placing bacteria at 65–75°C for 5–10 min; absence of CFU growth was confirmed by plating aliquots on THA. The multiplicity of infection (MOI) of GAS-to-cultured cells (immune and nonimmune cells) was 1:1 unless specified. Peritoneal exudate cells (PECs; ~30% macrophages and ~40% B cells), F244 fibrosarcoma, and HEK293 cells were cultured in RPMI 1640 containing 10% FBS with penicillin and streptomycin and switched to 2% FBS without antibiotics the day before the experiment. PECs were collected by lavage using 2.5 ml PBS or FACS buffer per peritoneum. Cell culture plates were spun at 1500 rpm for 5 min to facilitate contact between GAS and cultured cells. Cells were pretreated for 1 h with either NAC or ammonium pyrrolidine dithiocarbamate (PDTC) at a concentration of 0.6 and 0.4 μ M, respectively (Sigma-Aldrich). Final concentration of peptidoglycan was prepared as 1 μ g/ml (InvivoGen).

Flow cytometry experiments

Percentages of leukocytes within each sample were determined using a BD FACSCanto flow cytometer. CD45 (30-F11) and Ly-6G (1A8) markers were employed to identify neutrophils; CD45 and CD11b^{mid} (M1-70) for monocytes; CD45, CD11b^{high}, and F4/80 (BM8) for macrophages; NK1.1 (PK136) for NK cells; CD3 (145-2C11) for T cells; and CD45R (RA3-6B2) for B cells (all from BioLegend). Anti-CD192 (SA203G11) was used

to identify CCR2-positive cells (BioLegend). 7-Aminoactinomycin D-positive cells were used to identify dead cells (Calbiochem Research Biochemicals).

Quantitative real-time PCR

RNA was extracted using TRIzol (Life Technologies) or by using the Direct-zol RNA MiniPrep Kit (Zymogen). cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems); quantitative PCR data were generated using SYBR Green Master Mix (Applied Biosystems) with forward and reverse primers of indicated genes; reaction was run on the One Step Plus Real-Time PCR System (Applied Biosystems). Cycle threshold (Ct) values of *Hprt* or *Gapdh* reference gene of the vehicle or nontreated control samples were used in calculating the $\Delta\Delta$ Ct to determine the $2^{-\Delta\Delta$ Ct values. Primer sequences are listed in Supplemental Table I.

ELISA

Biopsies of kidney from WT and Il17d^{-/-} mice were weighed and homogenized in 1 ml PBS through a 70- μ m strainer. Tissue lysates were prepared by using radioimmunoprecipitation assay buffer (Teknova) with protease inhibitor and samples within the same experiment was normalized using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). Protein CCL2 was measured using a Quantikine ELISA Kit (R&D Systems) following the manufacturer's protocol. Standard curve was generated and applied to calculate picograms per milliliter CCL2, and fold difference was determined over mock infection.

Cytokine injection

C57BL/6 mice were maintained under specific pathogen-free conditions. A total of 0.5 μ g of IL-17D or IL-17A (R&D Systems) in 250 μ l PBS or vehicle in PBS were i.p. injected in each mouse. Bioactivity of these cytokines was confirmed previously in vivo (14). Heat-inactivated IL-17D was prepared by heating at 60°C for 30 min. Mice were euthanized using carbon dioxide, and peritoneal cavity was lavaged several times in total 10 ml PBS containing 1% FBS. Cells were incubated in RBC lysis buffer (BioLegend) and counted using the hemocytometer. To quantitate chemokine transcripts in mesothelial cells, peritoneal wall tissue was minced with scissors prior to the extraction of RNA. To analyze the mesothelial cell composition by flow cytometry, peritoneal wall tissues were minced with scissors and digested with collagenase (Worthington Biochemical) in medium overnight at 36.5°C.

Statistical analysis

All statistical analyses were processed through a statistical software package (GraphPad Prism). Kaplan–Meier survival curves were generated and analyzed using the log-rank test to assess statistical significance. CFU data from organ homogenates and lavage were analyzed using the non-parametric Mann–Whitney *U* test. In vitro GAS incubation experiments were analyzed using the Student two-tailed *t* test. All *p* values <0.05 were considered to be significant. The *p* values are denoted in figures as **p* < 0.05, ***p* < 0.01, and ****p* < 0.001.

Results

rIL-17D induces *ccl2* and recruitment of innate immune cells into the peritoneum

We hypothesized that IL-17D promotes rapid immune responses in part by inducing chemokines such as CCL2 and recruiting neutrophils. To establish our in vivo model system, we first tested the response of C57BL/6 WT mice to administration of purified rIL-17D into the peritoneal space. Injection of IL-17D induced significant amounts of *Ccl2* in peritoneal wall tissue (i.e., mesothelial cells) within 2 h (Fig. 1A). Other chemokines, such as *Cxcl3* and *Ccl7*, were also induced significantly after i.p. IL-17D injection (Supplemental Fig. 1A). Injection of rIL-17D also led to recruitment of early innate responders such as neutrophils and monocytes, which express CCR2 (Fig. 1B, Supplemental Fig. 1B, 1C). Accumulation of neutrophils peaked at 4 h, was induced also by IL-17A, and did not occur with heat-inactivated IL-17D (Fig. 1B, 1C, Supplemental Fig. 1D). Some chemokines that are induced by IL-17D, such as *Ccl2* and *Ccl7*, can also be induced by i.p. IL-17A injection and led to similar recruitment of cells such as monocytes




FIGURE 1. rIL-17D induces *Ccl2* and recruits innate immune cells into the peritoneum. **(A)** Relative *Ccl2* transcript in peritoneal wall tissue (mesothelial cells) hours after i.p. IL-17D injection ($n = 4$). **(B)** Total peritoneal exudate neutrophils ($n = 4$) recovered hours after i.p. IL-17D injection. **(C)** Neutrophils recovered in peritoneal exudate after 4 h i.p. IL-17D versus IL-17A ($n = 3$). Data are combined from two experiments. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

(Supplemental Fig. 1E, 1F), confirming that the peritoneal space could respond to IL-17 family cytokines. Notably, the peritoneal wall cells responding to IL-17 family cytokines are likely resident mesothelial cells because we did not detect significant levels of immune cells within the peritoneal wall by flow cytometry (Supplemental Fig. 1G).

Il17d^{-/-} mice display slightly compromised responses to bacterial infection

Having established that nonimmune cells in the peritoneum could respond to IL-17D, we next assessed the requirement for IL-17D in antibacterial responses in which the bacteria are introduced into the peritoneum (i.p.). After i.p. infection with GAS, we monitored WT and *Il17d*^{-/-} mice for survival and weight loss. We observed slightly higher weight loss in *Il17d*^{-/-} mice infected by GAS (Fig. 2A, 2B). We also observed a lower survival rate of *Il17d*^{-/-} mice at the maximum GAS dose tested (5×10^7), but this did not achieve statistical significance (Fig. 2C).

Previously we had observed that *Il17d*^{-/-} mice manifest higher viral burden in some organs after murine CMV infection (17). Therefore, we examined bacterial burden in multiple tissues after GAS infection. Indeed, the kidney and peritoneal cavity harbored significantly higher GAS CFU in *Il17d*^{-/-} mice (Fig. 3A, 3B, Supplemental Fig. 2A). The higher bacterial burdens in the kidneys of *Il17d*^{-/-} animals was confirmed through three different challenge doses of GAS (Fig. 3C). The difference in bacterial burden was largest at 24 h, and not at later times (Supplemental Fig. 2B). We did not detect significant differences in bacterial burden between WT and *Il17d*^{-/-} mice in organs such as the heart, lung, and spleen (Supplemental Fig. 2C).

Phenotype of kidney after i.p. infection of *Il17d*^{-/-} mice

Our results above suggest the kidney may be an organ site that depends on IL-17D for local immunity. Indeed, *Il17d*, but not *Il17a*, transcript was induced in the kidney of WT mice infected with GAS at 4 and 24 h after i.p. injection (Fig. 3D, Supplemental

Fig. 2D). This induction led to higher *Ccl2* transcript and CCL2 protein in WT compared with *Il17d*^{-/-} mice (Fig. 3E, Supplemental Fig. 2E), suggesting that IL-17D production in the kidney had functional consequences on chemokine production. We found *Il17d*^{-/-} mice to have slightly decreased overall immune cell in the infected kidney, which coincided with lower *Ccl2* protein. Specifically, there was a trend for decreased CD45⁺ cells and neutrophils, but not macrophages (Fig. 3F–H), in the kidneys of IL-17D-deficient mice compared with WT mice infected with GAS. However, Ab neutralization of CCL2 in WT mice did not lead to higher bacterial burden we saw in *Il17d*^{-/-} kidney and peritoneum (Supplemental Fig. 2F, 2G). Furthermore, blocking of CCL2 alone did not compromise immune cell recruitment into the kidney (Supplemental Fig. 2H, 2I). Because IL-17D can induce chemokines such as *Cxcl3*, *Cxcl2*, and *Ccl7* in vivo (Supplemental Fig. 1A), we surveyed for transcripts of other downstream effectors that could potentially substitute for CCL2 in WT versus *Il17d*^{-/-} kidneys (Supplemental Fig. 2D). Although we found some differences, no single chemokine emerged as clearly responsible for recruiting immune cells in the kidney. In the peritoneum, we found no difference in the absolute numbers of recruited neutrophils and macrophages between WT and *Il17d*^{-/-} mice (Supplemental Fig. 2J, 2K), although we found *Ccl2* transcript was significantly greater in recruited WT peritoneal cells compared with those in *Il17d*^{-/-} mice (Supplemental Fig. 2L).

Viable, but not nonviable, GAS induces IL-17D in nonimmune cells

Because the response to GAS differed between locations that had relatively high (peritoneum) versus low (kidney) cellularity in immune cells, we explored the induction of *Il17d* in immune versus nonimmune tissues. We performed a short-term ex vivo infection of PECs and compared with in vitro infection of epithelial cell lines from mouse and human origin. At an MOI of 1:1, GAS challenge was sufficient to elicit increases in *Il17d* transcript in a renal epithelial cell line (HEK293) and PECs (Fig. 4A, 4B).




FIGURE 2. GAS-infected *Il17d*^{-/-} mice have slight weight loss and a decreased survival rate compared with WT mice. **(A)** Percent weight loss of WT and *Il17d*^{-/-} mice ($n = 3$) after 5×10^6 , 1×10^7 , and 2×10^7 i.p. GAS doses. **(B)** Percent weight loss and **(C)** percent survival of WT ($n > 6$) versus *Il17d*^{-/-} ($n > 8$) mice after 5×10^7 dose of GAS i.p. Data are combined from at least two independent experiments. The p value in (B) corresponds to the day 5 timepoint. * $p < 0.05$.




FIGURE 3. An i.p. injection of GAS into *Il17d*^{-/-} mice results in increased bacterial burden in kidney. Bacterial CFU burden in (A) kidney homogenates and (B) peritoneal cavity at 24 h after GAS infection (dose = 10×10^6) in WT and *Il17d*^{-/-} mice ($n > 5$). (C) CFU recovered in kidney ($n = 3$) after 24 h of three doses (6×10^6 , 8×10^6 , and 10×10^6) of GAS i.p. (D) Relative ex vivo *Il17d* transcript in the GAS-infected kidney of WT mice compared with PBS control injection group ($n = 4$). (E) Relative *Ccl2* transcript of WT and *Il17d*^{-/-} kidney from GAS-infected mice ($n = 3-5$). (F) Percentage of CD45⁺ cells and absolute (G) neutrophil and (H) macrophage numbers in the kidney from uninfected ($n = 2-4$) and 24 h-postinfected ($n = 4-6$) WT and *Il17d*^{-/-} mice. Data are combined data of at least two independent experiments. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Induction of *Il17d* in nonimmune cells was ablated when the bacteria were heat killed (Fig. 4A). In contrast, both alive and heat-killed GAS stimulated similar increases in *Il17d* transcript in PECs (immune cells), which are mostly macrophages and B cells (Fig. 4B). Because live bacteria could replicate, we next asked whether the selective induction of IL-17D by live bacteria was a result of increased burden. We found that throughout the time course of the 3-h assay, there was an ~6-fold increase in live bacteria (Supplemental Fig. 3A). Therefore, we titrated the amount of alive or dead bacteria to test whether selective induction of *Il17d* by live versus dead bacteria was due to differences in quantity of bacteria. We found that decreasing the amount of live bacteria 16-fold could still induce *Il17d* better than killed bacteria in epithelial and sarcoma cells (Fig. 4C, Supplemental Fig. 3B), but not in PECs (Fig. 4D). In addition, spiking the assay with additional dead GAS did not increase *Il17d* transcriptional responses in renal epithelial cells, although it was sufficient for commensurate increases in the inflammatory cytokine *Tnf* as a control (Fig. 4E). Similar to dead GAS bacteria, the bacterial cell wall component peptidoglycan did not induce *Il17d*, whereas *Tnf* transcript rose after peptidoglycan treatment or with living or heat-killed GAS (Fig. 4F).

IL-17D induction by viable bacterial requires production of ROS in nonimmune cells

We previously found that oxidative stress, via the transcription factor *Nrf2*, could induce IL-17D (16). As viable GAS stimulates

oxidative stress through ROS production (36, 37, 42), we next tested whether treating the infected cells with an ROS scavenger attenuated the levels of IL-17D induced. We confirmed that IL-17D is induced in epithelial cells infected by live GAS, whereas two different ROS scavengers, NAC and PDTC, independently abrogated the effect (Fig. 5A). Notably, *Il17d* induction in immune cells (PECs) were not affected by ROS scavengers, regardless of whether GAS was alive or dead (Supplemental Fig. 3C). At this early time point, ROS scavengers in the culture medium did not block host cell death induced by GAS cytolytic toxins or have an inhibitory effect on GAS growth during the experiment (Supplemental Fig. 3D, 3E).

To test whether ROS scavenger compromises immune responses to bacterial infection, NAC was injected preceding GAS inoculation. We found significantly higher bacterial burden in the kidney but not in the peritoneum in WT mice (Fig. 5B, 5C). Furthermore, *Il17d* and *Ccl2* transcripts and neutrophil infiltration in the NAC-treated mice were lower compared with control-infected mice (Fig. 5D, 5E).

Discussion

To apply swift action to fight off pathogens, immune cells recognize pathogen-associated molecular patterns (PAMPs) through pattern recognition receptors (PRRs) leading to effector activities such as production of cytokines (43–46). Most PRRs can respond to dead organisms and even specific molecular components of pathogens.




FIGURE 4. Viable GAS induces IL-17D in nonimmune cells. **(A)** Relative *Il17d* transcript in HEK293 cells and **(B)** PECs after 2 h in vitro incubation with the indicated MOI using living (alive) or heat-killed (dead) GAS ($n = 3$). **(C)** Relative *Il17d* transcript in the HEK293 and **(D)** PECs after 3-h incubation with decreasing GAS infection ratio (maximum MOI of dead and alive is 1:1) ($n = 3$). **(E)** Relative *Il17d* and *Tnf* in HEK293 cells incubated with increasing ratio of heat-killed GAS ($n = 3$). **(F)** HEK293 cells were incubated with peptidoglycan (PGN), dead GAS (8:1), and living GAS (1:1), and transcript levels of *Il17d* and *Tnf* were measured ($n = 3$). Data are representative data of at least three independent experiments. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.


Our data suggest an immune trigger that relies on bacterial viability in addition to PAMPs. Indeed, increasing evidence point to demonstrable distinction between PAMPs produced by the living versus the dead (47–51). By recognizing molecular by-products produced by viable replicating pathogens, the immune response can discriminate between harmless patterns among the normal microbiota and harmful infection (52, 53). Although we have shown that oxidative stress due to viable infection can elicit one specific cytokine (IL-17D), we envision that a more generalizable paradigm could emerge in which other stress pathways, such as metabolic and proteotoxic stress, could also induce cytokine secretion (54) postinfection by viable, but not nonviable, organisms. Thus, certain immune responses initiate only after the overall stress of infection surpasses a threshold. In this way, rather than passively recognizing a pattern or Ag that the pathogen contains, the host cell must undergo stress to appropriately respond. Indeed,

this paradigm was shown to control the expression of NKG2D ligands, which can be induced by genotoxic stress (55–57).

The PRRs that orchestrate the immune response to GAS are not clearly defined (58–60). Although TLR2 recognizes peptidoglycans found in Gram-positive bacteria (including GAS), it is not required for immune responses to GAS (58). TLR13 in macrophages is required to recognize GAS bacterial RNA in mice (61), and TLR9 recognition of GAS DNA is key to host defense against the pathogen (62). Activation may depend on other components as well because C-type lectin receptor expressed by macrophages mediates cytokine production by detecting GAS lipoteichoic acid (63).

GAS is known to induce ROS and oxidative stress caused by invasion-triggered caspases, and ROS production is linked with cell death in macrophages and epithelial cells following GAS infection (36, 37, 42). Attenuated ROS production has been observed in

FIGURE 5. ROS scavenger suppresses induction of IL-17D in active GAS infection. **(A)** Relative *Il17d* transcript in the HEK293 cells ($n = 3$) pretreated with ROS scavengers (NAC and PDTC) prior to incubating with GAS (1:1 alive; 4:1 dead). **(B)** Kidney and **(C)** peritoneal cavity bacterial CFU burden after 16 h from GAS-infected and ROS scavenger–treated mice ($n > 4$). **(D)** Relative kidney *Il17d* and *Ccl2* transcript in infected mice pretreated with ROS scavenger ($n = 3$). **(E)** Absolute numbers of kidney neutrophils in GAS-infected mice with or without ROS scavenger ($n > 3$). Data are combined data of at least two independent experiments. * $p < 0.05$, *** $p < 0.001$.



epithelial cells infected by adhesion-incompetent or heat-killed GAS (36, 37, 64). We have previously reported that oxidative stress can lead to IL-17D expression via the activation of the antioxidant transcription factor, Nrf2 (16, 17). Altogether, our studies suggest that viable GAS infection induces ROS, leading to oxidative stress and Nrf2 induction, which results in secretion of IL-17D and innate immune responses.

Given that Nrf2 responds to oxidative stress and is critical in protecting cells against ROS-mediated damage, the role of Nrf2 in bacterial immunity is complex (65). For example, in a sepsis model, Nrf2 deficiency results in far higher mortality rate, sensitivity to inflammation by LPS and TNF, and induction of proinflammatory genes (66). In addition to the global changes to the immunoreactivity of Nrf2^{-/-} mice, Nrf2-deficient alveolar macrophages are compromised in phagocytic uptake of microbes such as *Pseudomonas aeruginosa* (67). In contrast, Gomez and colleagues (68) report that mice lacking Nrf2 had increased phagocytic activity at baseline but had compromised immune activation and increased mortality after lung infection by *S. pneumoniae*. It is not clear whether this increased mortality is due to insufficient cell-protective antioxidant responses or the lack of IL-17D induction. Although clearly Nrf2 is important for immunity, further studies are needed to clarify the impact of IL-17D in Nrf2-mediated responses.

We demonstrated that Il17d^{-/-} mice are more prone to increased death and weight loss upon opportunistic GAS infection, although with a modest presentation. In addition, the loss of IL-17D resulted in phenotypes limited to some organs such as the kidney, but not in organs such as the spleen and lung. Cytokines in the IL-17 family induces effector molecules that are generally overlapping in similar targets (3, 4, 5). So far, it is known that IL-17A, IL-17F, IL-17E, and IL-17C share at least one receptor subunit, IL-17RA, for signal transduction (2). We speculate that IL-17D is dispensable in spleen and lung because IL-17A is sufficient to confer protection in those organs. In fact, lacking IL-17A in the lung and spleen has been shown to delay and limit neutrophil recruitment postinfection by pathogens (69, 70). Furthermore, although IL-17RA and IL-17RC (receptors for IL-17A/F) are protective in candidiasis, IL-17RE (IL-17C cognate receptor) does not confer protection (71). These observations suggest that some IL-17 cytokines are redundant in tissues with overlapping expression patterns.

Similar to IL-17D, IL-17A promotes neutrophil migration and is generally known to participate in antipathogen immunity. However, IL-17A/F and IL-17C promote LPS-induced toxic shock, whereas IL-17D does not (72–74). Therefore, in addition to overlapping functions of IL-17 cytokines, the degree of inflammation promoted by each may differ by scale. In light of these previous findings, we speculate that the modest effect of IL-17D is attributable, in part, to the complex overlaps in downstream effectors among proinflammatory cytokines and especially those within the IL-17 family.

We measured increases in *Il17d* and *Ccl2* upon in vivo GAS infection of the WT kidney and detected a trend for lower neutrophil infiltration and relatively lower *Ccl2* transcript and protein in the kidneys of Il17d^{-/-} compared with WT mice. Because blocking *Ccl2* protein did not compromise infiltration or bacterial clearance, we surmise that IL-17D can induce other chemokines that work together to recruit the appropriate immune response, perhaps redundantly. Indeed, rIL-17D induced a plethora of chemokines, including *Cxcl3*, *Ccl7*, and *Ccl5*. We speculate that the fact that the kidney harbors a relatively low ratio of immune cells to nonimmune cells when compared with organs such as lungs and spleen explains its reliance on IL-17D-induced chemokines for

antipathogen immunity. Thus, Il17d^{-/-} mice may face greatest disadvantage in warding off bacterial infection in organs dependent on effective recruitment of early active responders. Notably, unregulated IL-17D production in locations that have low levels of resident immune cell could lead to pathologic conditions. Therefore, it is logical to place a checkpoint in nonimmune cells, limiting their production of IL-17D only during live infection, as we have shown. This live/dead checkpoint could serve as a paradigm to regulate immune responses in tissues with low levels of immunity but that may also harbor commensal organisms.

Disclosures

The authors have no financial conflicts of interest.

References

- Kolls, J. K., and A. Lindén. 2004. Interleukin-17 family members and inflammation. *Immunity* 21: 467–476.
- McGeachy, M. J., D. J. Cua, and S. L. Gaffen. 2019. The IL-17 family of cytokines in health and disease. *Immunity* 50: 892–906.
- Starnes, T., H. E. Broxmeyer, M. J. Robertson, and R. Hromas. 2002. Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. *J. Immunol.* 169: 642–646.
- Ramirez-Carrozzi, V., A. Sambandam, E. Luis, Z. Lin, S. Jeet, J. Lesch, J. Hackney, J. Kim, M. Zhou, J. Lai, et al. 2011. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. *Nat. Immunol.* 12: 1159–1166.
- Yamaguchi, Y., K. Fujio, H. Shoda, A. Okamoto, N. H. Tsuno, K. Takahashi, and K. Yamamoto. 2007. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. *J. Immunol.* 179: 7128–7136.
- Johnston, A., Y. Fritz, S. M. Dawes, D. Diaconu, P. M. Al-Attar, A. M. Guzman, C. S. Chen, W. Fu, J. E. Gudjonsson, T. S. McCormick, and N. L. Ward. 2013. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. *J. Immunol.* 190: 2252–2262.
- Aujla, S. J., Y. R. Chan, M. Zheng, M. Fei, D. J. Askew, D. A. Pociask, T. A. Reinhart, F. McAllister, J. Deale, K. Gaus, et al. 2008. IL-22 mediates mucosal host defense against gram-negative bacterial pneumonia. *Nat. Med.* 14: 275–281.
- Hamada, S., M. Umehura, T. Shiono, K. Tanaka, A. Yahagi, M. D. Begum, K. Oshiro, Y. Okamoto, H. Watanabe, K. Kawakami, et al. 2008. IL-17A produced by gammadelta T cells plays a critical role in innate immunity against listeria monocytogenes infection in the liver. *J. Immunol.* 181: 3456–3463.
- Shibata, K., H. Yamada, H. Hara, K. Kishihara, and Y. Yoshikai. 2007. Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after *Escherichia coli* infection via IL-17 production. *J. Immunol.* 178: 4466–4472.
- Song, X., S. Zhu, P. Shi, Y. Liu, Y. Shi, S. D. Levin, and Y. Qian. 2011. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. *Nat. Immunol.* 12: 1151–1158.
- Ishigame, H., S. Kakuta, T. Nagai, M. Kadoki, A. Nambu, Y. Komiyama, N. Fujikado, Y. Tanahashi, A. Akitsu, H. Kotaki, et al. 2009. Differential roles of interleukin-17A and -17F in host defense against mucocutaneous bacterial infection and allergic responses. *Immunity* 30: 108–119.
- Fallon, P. G., S. J. Ballantyne, N. E. Mangan, J. L. Barlow, A. Dasvarma, D. R. Hewett, A. McIlgorm, H. E. Jolin, and A. N. McKenzie. 2006. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. *J. Exp. Med.* 203: 1105–1116.
- Reynolds, J. M., Y. H. Lee, Y. Shi, X. Wang, P. Angkasekwinai, K. C. Nallaparaju, S. Flaherty, S. H. Chang, H. Watarai, and C. Dong. 2015. Interleukin-17B antagonizes interleukin-25-mediated mucosal inflammation. *Immunity* 42: 692–703.
- O'Sullivan, T., R. Saddawi-Konefka, E. Gross, M. Tran, S. P. Mayfield, H. Ikeda, and J. D. Bui. 2014. Interleukin-17D mediates tumor rejection through recruitment of natural killer cells. *Cell Rep.* 7: 989–998.
- Saddawi-Konefka, R., T. O'Sullivan, E. T. Gross, A. Washington, Jr., and J. D. Bui. 2015. Tumor-expressed IL-17D recruits NK cells to reject tumors. *OncolImmunol.* 3: e954853.
- Saddawi-Konefka, R., R. Seelige, E. T. Gross, E. Levy, S. C. Searles, A. Washington, Jr., E. K. Santosa, B. Liu, T. E. O'Sullivan, O. Harismendy, and J. D. Bui. 2016. Nrf2 induces IL-17D to mediate tumor and virus surveillance. *Cell Rep.* 16: 2348–2358.
- Seelige, R., R. Saddawi-Konefka, N. M. Adams, G. Picarda, J. C. Sun, C. A. Benedict, and J. D. Bui. 2018. Interleukin-17D and Nrf2 mediate initial innate immune cell recruitment and restrict MCMV infection. *Sci. Rep.* 8: 13670.
- Seelige, R., A. Washington, Jr., and J. D. Bui. 2017. The ancient cytokine IL-17D is regulated by Nrf2 and mediates tumor and virus surveillance. *Cytokine* 91: 10–12.
- Kono, T., H. Korenaga, and M. Sakai. 2011. Genomics of fish IL-17 ligand and receptors: a review. *Fish Shellfish Immunol.* 31: 635–643.
- Kumari, J., A. N. Larsen, J. Bogwald, and R. A. Dalmo. 2009. Interleukin-17D in Atlantic salmon (*Salmo salar*): molecular characterization, 3D modelling and promoter analysis. *Fish Shellfish Immunol.* 27: 647–659.

21. Tsutsui, S., O. Nakamura, and T. Watanabe. 2007. Lamprey (Lethenteron japonicum) IL-17 upregulated by LPS-stimulation in the skin cells. *Immunogenetics* 59: 873–882.
22. Roberts, S., Y. Gueguen, J. de Lorgeril, and F. Goetz. 2008. Rapid accumulation of an interleukin 17 homolog transcript in *Crassostrea gigas* hemocytes following bacterial exposure. *Dev. Comp. Immunol.* 32: 1099–1104.
23. Zhang, Q. L., Q. H. Zhu, M. Z. Liang, F. Wang, J. Guo, X. Y. Deng, J. Y. Chen, Y. J. Wang, and L. B. Lin. 2018. Comparative transcriptomic analysis provides insights into antibacterial mechanisms of *Branchiostoma belcheri* under *Vibrio parahaemolyticus* infection. *Fish Shellfish Immunol.* 76: 196–205.
24. Rouvier, E., M. F. Luciani, M. G. Mattéi, F. Denizot, and P. Golstein. 1993. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. *J. Immunol.* 150: 5445–5456.
25. Ivanov, I. I., B. S. McKenzie, L. Zhou, C. E. Tadokoro, A. Lepelletier, J. J. Lafaille, D. J. Cua, and D. R. Littman. 2006. The orphan nuclear receptor ROR γ directs the differentiation program of proinflammatory IL-17+ T helper cells. *Cell* 126: 1121–1133.
26. Yang, X. O., B. P. Pappu, R. Nurieva, A. Akimzhanov, H. S. Kang, Y. Chung, L. Ma, B. Shah, A. D. Panopoulos, K. S. Schluns, et al. 2008. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR α and ROR γ . *Immunity* 28: 29–39.
27. Pfeifer, P., M. Voss, B. Wonnemberg, J. Hellberg, F. Seiler, P. M. Lepper, M. Bischoff, F. Langer, H. J. Schäfers, M. D. Menger, et al. 2013. IL-17C is a mediator of respiratory epithelial innate immune response. *Am. J. Respir. Cell Mol. Biol.* 48: 415–421.
28. von Moltke, J., M. Ji, H. E. Liang, and R. M. Locksley. 2016. Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit. *Nature* 529: 221–225.
29. Nadjisombati, M. S., J. W. McGinty, M. R. Lyons-Cohen, J. B. Jaffe, L. DiPeso, C. Schneider, C. N. Miller, J. L. Pollack, G. A. Nagana Gowda, M. F. Fontana, et al. 2018. Detection of succinate by intestinal tuft cells triggers a type 2 innate immune circuit. *Immunity* 49: 33–41.e7.
30. Walker, M. J., T. C. Barnett, J. D. McArthur, J. N. Cole, C. M. Gillen, A. Henningham, K. S. Sriprakash, M. L. Sanderson-Smith, and V. Nizet. 2014. Disease manifestations and pathogenic mechanisms of Group A *Streptococcus*. *Clin. Microbiol. Rev.* 27: 264–301.
31. Carapetis, J. R., A. Beaton, M. W. Cunningham, L. Guilherme, G. Karthikeyan, B. M. Mayosi, C. Sable, A. Steer, N. Wilson, R. Wyber, and L. Zühlke. 2016. Acute rheumatic fever and rheumatic heart disease. *Nat. Rev. Dis. Primers* 2: 15084.
32. Stevens, D. L., and A. E. Bryant. 2016. Severe group A streptococcal infections. In *Streptococcus pyogenes: Basic Biology to Clinical Manifestations*. J. J. Ferretti, D. L. Stevens, and V. A. Fischetti, eds. University of Oklahoma Health Sciences Center, Oklahoma City, OK.
33. Rohde, M., and P. P. Cleary. 2016. Adhesion and invasion of *Streptococcus pyogenes* into host cells and clinical relevance of intracellular streptococci. In *Streptococcus pyogenes: Basic Biology to Clinical Manifestations*. J. J. Ferretti, D. L. Stevens, and V. A. Fischetti, eds. University of Oklahoma Health Sciences Center, Oklahoma City, OK.
34. Valderrama, J. A., and V. Nizet. 2018. Group A *Streptococcus* encounters with host macrophages. *Future Microbiol.* 13: 119–134.
35. Valderrama, J. A., A. M. Riestra, N. J. Gao, C. N. LaRock, N. Gupta, S. R. Ali, H. M. Hoffman, P. Ghosh, and V. Nizet. 2017. Group A streptococcal M protein activates the NLRP3 inflammasome. *Nat. Microbiol.* 2: 1425–1434.
36. Aikawa, C., T. Nozawa, F. Maruyama, K. Tsumoto, S. Hamada, and I. Nakagawa. 2010. Reactive oxygen species induced by *Streptococcus pyogenes* invasion trigger apoptotic cell death in infected epithelial cells. *Cell. Microbiol.* 12: 814–830.
37. Regnier, E., P. A. Grange, G. Ollagnier, E. Crickx, L. Elie, S. Chouzenoux, B. Weill, C. Plainvert, C. Poyart, F. Batteux, and N. Dupin. 2016. Superoxide anions produced by *Streptococcus pyogenes* group A-stimulated keratinocytes are responsible for cellular necrosis and bacterial growth inhibition. *Innate Immun.* 22: 113–123.
38. Tsatsaronis, J. A., M. J. Walker, and M. L. Sanderson-Smith. 2014. Host responses to group A streptococcus: cell death and inflammation. *PLoS Pathog.* 10: e1004266.
39. Tsai, P. J., Y. S. Lin, C. F. Kuo, H. Y. Lei, and J. J. Wu. 1999. Group A *Streptococcus* induces apoptosis in human epithelial cells. *Infect. Immun.* 67: 4334–4339.
40. Chatellier, S., N. Ihendyane, R. G. Kansal, F. Khambaty, H. Basma, A. Norrby-Teglund, D. E. Low, A. McGeer, and M. Kotb. 2000. Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. *Infect. Immun.* 68: 3523–3534.
41. Aziz, R. K., and M. Kotb. 2008. Rise and persistence of global MIT1 clone of *Streptococcus pyogenes*. *Emerg. Infect. Dis.* 14: 1511–1517.
42. Fieber, C., and P. Kovarik. 2014. Responses of innate immune cells to group A *Streptococcus*. *Front. Cell. Infect. Microbiol.* 4: 140.
43. Tang, D., R. Kang, C. B. Coyne, H. J. Zeh, and M. T. Lotze. 2012. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. *Immunol. Rev.* 249: 158–175.
44. Akira, S., and H. Hemmi. 2003. Recognition of pathogen-associated molecular patterns by TLR family. *Immunol. Lett.* 85: 85–95.
45. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A toll-like receptor recognizes bacterial DNA. *Nature* 408: 740–745.
46. Medzhitov, R., and C. A. Janeway, Jr. 2002. Decoding the patterns of self and nonself by the innate immune system. *Science* 296: 298–300.
47. Vance, R. E., R. R. Isberg, and D. A. Portnoy. 2009. Patterns of pathogenesis: discrimination of pathogenic and nonpathogenic microbes by the innate immune system. *Cell Host Microbe* 6: 10–21.
48. Sander, L. E., M. J. Davis, M. V. Boekschoten, D. Amsen, C. C. Dascher, B. Ryffel, J. A. Swanson, M. Müller, and J. M. Blander. 2011. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. [Published erratum appears in 2011 *Nature* 478: 136.] *Nature* 474: 385–389.
49. Moretti, J., S. Roy, D. Bozec, J. Martinez, J. R. Chapman, B. Ueberheide, D. W. Lamming, Z. J. Chen, T. Horg, G. Yeretsian, et al. 2017. STING senses microbial viability to orchestrate stress-mediated autophagy of the endoplasmic reticulum. *Cell* 171: 809–823.e13.
50. Jensen, K., I. J. Gallagher, A. Kaliszewska, C. Zhang, O. Abejide, M. P. Gallagher, D. Werling, and E. J. Glass. 2016. Live and inactivated *Salmonella enterica* serovar Typhimurium stimulate similar but distinct transcriptome profiles in bovine macrophages and dendritic cells. *Vet. Res. (Faisalabad)* 47: 46.
51. Cruciani, M., S. Sandini, M. P. Etna, E. Giacomini, R. Camilli, M. Severa, F. Rizzo, F. Bagnoli, J. Hiscott, and E. M. Coccia. 2019. Differential responses of human dendritic cells to live or inactivated *Staphylococcus aureus*: impact on cytokine production and T helper expansion. *Front. Immunol.* 10: 2622.
52. Ugolini, M., and L. E. Sander. 2019. Dead or alive: how the immune system detects microbial viability. *Curr. Opin. Immunol.* 56: 60–66.
53. Blander, J. M., and L. E. Sander. 2012. Beyond pattern recognition: five immune checkpoints for scaling the microbial threat. *Nat. Rev. Immunol.* 12: 215–225.
54. Seeliger, R., S. Searles, and J. D. Bui. 2018. Innate sensing of cancer's non-immunologic hallmarks. *Curr. Opin. Immunol.* 50: 1–8.
55. Spear, P., M. R. Wu, M. L. Sentman, and C. L. Sentman. 2013. NKG2D ligands as therapeutic targets. *Cancer Immun.* 13: 8.
56. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. *Science* 285: 727–729.
57. Gasser, S., S. Orsulic, E. J. Brown, and D. H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. *Nature* 436: 1186–1190.
58. Gratz, N., M. Siller, B. Schaljo, Z. A. Pirzada, I. Gattermeier, I. Vojtek, C. J. Kirschning, H. Wagner, S. Akira, E. Charpentier, and P. Kovarik. 2008. Group A streptococcus activates type I interferon production and MyD88-dependent signaling without involvement of TLR2, TLR4, and TLR9. *J. Biol. Chem.* 283: 19879–19887.
59. Harder, J., L. Franchi, R. Muñoz-Planillo, J. H. Park, T. Reimer, and G. Núñez. 2009. Activation of the Nlrp3 inflammasome by *Streptococcus pyogenes* requires streptolysin O and NF- κ B activation but proceeds independently of TLR signaling and P2X7 receptor. *J. Immunol.* 183: 5823–5829.
60. Loof, T. G., O. Goldmann, and E. Medina. 2008. Immune recognition of *Streptococcus pyogenes* by dendritic cells. *Infect. Immun.* 76: 2785–2792.
61. Fieber, C., M. Janos, T. Koestler, N. Gratz, X. D. Li, V. Castiglia, M. Aberle, M. Sauert, M. Wegner, L. Alexopoulou, et al. 2015. Innate immune response to *Streptococcus pyogenes* depends on the combined activation of TLR13 and TLR2. *PLoS One* 10: e0119727.
62. Zinkernagel, A. S., P. Hruz, S. Uchiyama, M. von Köckritz-Blickwede, R. A. Schuepbach, T. Hayashi, D. A. Carson, and V. Nizet. 2012. Importance of toll-like receptor 9 in host defense against MIT1 group A *Streptococcus* infections. *J. Innate Immun.* 4: 213–218.
63. Imai, T., T. Matsumura, S. Mayer-Lambertz, C. A. Wells, E. Ishikawa, S. K. Butcher, T. C. Barnett, M. J. Walker, A. Imamura, H., et al. 2018. Lipoteichoic acid anchor triggers Mincle to drive protective immunity against invasive group A *Streptococcus* infection. *Proc. Natl. Acad. Sci. USA* 115: E10662–E10671.
64. Boncompain, G., B. Schneider, C. Delevoye, O. Kellermann, A. Dautry-Varsat, and A. Subtil. 2010. Production of reactive oxygen species is turned on and rapidly shut down in epithelial cells infected with *Chlamydia trachomatis*. *Infect. Immun.* 78: 80–87.
65. Battino, M., F. Giampieri, F. Pistollato, A. Sureda, M. R. de Oliveira, V. Pittalà, F. Fallarino, S. F. Nabavi, A. G. Atanasov, and S. M. Nabavi. 2018. Nrf2 as regulator of innate immunity: a molecular Swiss army knife! *Biotechnol. Adv.* 36: 358–370.
66. Thimmulappa, R. K., H. Lee, T. Rangasamy, S. P. Reddy, M. Yamamoto, T. W. Kensler, and S. Biswal. 2006. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. *J. Clin. Invest.* 116: 984–995.
67. Harvey, C. J., R. K. Thimmulappa, S. Sethi, X. Kong, L. Yarmus, R. H. Brown, D. Feller-Kopman, R. Wise, and S. Biswal. 2011. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. *Sci. Transl. Med.* 3: 78ra32.
68. Gomez, J. C., H. Dang, J. R. Martin, and C. M. Doerschuk. 2016. Nrf2 modulates host defense during *Streptococcus pneumoniae* pneumonia in mice. *J. Immunol.* 197: 2864–2879.
69. Ye, P., F. H. Rodriguez, S. Kanaly, K. L. Stocking, J. Schurr, P. Schwarzenberger, P. Oliver, W. Huang, P. Zhang, J. Zhang, et al. 2001. Requirement of interleukin 17 receptor signaling for lung CXCL chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. *J. Exp. Med.* 194: 519–527.
70. Tosello Boari, J., M. C. Amezcua Vesely, D. A. Bermejo, M. C. Ramello, C. L. Montes, H. Cejas, A. Gruppi, and E. V. Acosta Rodríguez. 2012. IL-17RA

- signaling reduces inflammation and mortality during *Trypanosoma cruzi* infection by recruiting suppressive IL-10-producing neutrophils. *PLoS Pathog.* 8: e1002658.
71. Conti, H. R., N. Whibley, B. M. Coleman, A. V. Garg, J. R. Jaycox, and S. L. Gaffen. 2015. Signaling through IL-17C/IL-17RE is dispensable for immunity to systemic, oral and cutaneous candidiasis. *PLoS One* 10: e0122807.
 72. Yamaguchi, S., A. Nambu, T. Numata, T. Yoshizaki, S. Narushima, E. Shimura, Y. Hiraishi, K. Arae, H. Morita, K. Matsumoto, et al. 2018. The roles of IL-17C in T cell-dependent and -independent inflammatory diseases. *Sci. Rep.* 8: 15750.
 73. Haque, A., Y. Ishii, Y. Akasaka, T. Matsumoto, and K. Tateda. 2017. Administration of colistin sulfate in endotoxic model at slow and sustained fashion may reverse shock without causing nephrotoxicity in its optimal concentration. *J. Glob. Antimicrob. Resist.* 11: 40–44.
 74. Lee, Y., J. Clinton, C. Yao, and S. H. Chang. 2019. Interleukin-17D promotes pathogenicity during infection by suppressing CD8 T cell activity. *Front. Immunol.* 10: 1172.